INO: INO-3107 shows strong efficacy for RRP, with FDA decision and commercialization plans imminent
The discussion highlighted a proprietary DNA medicines platform with a lead candidate, INO-3107, nearing a pivotal FDA decision for RRP. Strong clinical efficacy, a favorable safety profile, and commercial readiness position the program for significant market impact, with a robust pipeline and cash…